Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Jan;21(1):19–26. doi: 10.1111/j.1365-2125.1986.tb02818.x

The effect of liver microsomal enzyme inducing and inhibiting drugs on insulin mediated glucose metabolism in man.

J T Lahtela, B Gachalyi, S Eksymä, A Hämäläinen, E A Sotaniemi
PMCID: PMC1400813  PMID: 3511933

Abstract

The effects of hepatic microsomal enzyme inducing (phenobarbitone and flumecinol), and inhibiting (cimetidine) drugs, and placebo treatment on insulin mediated glucose metabolism (M) were investigated in 29 healthy volunteers. Phenobarbitone (50 mg for 10 days) increased M (30%), metabolic clearance rate of glucose (MCRg), and antipyrine clearance rate (33%). Fasting immunoreactive insulin (IRI) decreased while fasting blood glucose (BG) remained unaltered. Flumecinol, another inducer, tested in two doses (200 mg and 600 mg for 6 days), did not alter glucose or antipyrine metabolism. Fasting IRI reduced on treatment with 600 mg of flumecinol, but not with the smaller dose. Cimetidine (600 mg for 6 days) decreased M (19.5%), MCRg (26%), and antipyrine clearance rate (20%). The placebo did not alter glucose or antipyrine metabolism. The results indicate that the insulin mediated glucose disposal rate can be altered by drugs influencing hepatic microsomal enzyme activity.

Full text

PDF
19

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arner P., Einarsson K., Backman L., Nilsell K., Lerea K. M., Livingston J. N. Studies of liver insulin receptors in non-obese and obese human subjects. J Clin Invest. 1983 Nov;72(5):1729–1736. doi: 10.1172/JCI111132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beck-Nielsen H., Pedersen O., Lindskov H. O. Normalization of the insulin sensitivity and the cellular insulin binding during treatment of obese diabetics for one year. Acta Endocrinol (Copenh) 1979 Jan;90(1):103–112. doi: 10.1530/acta.0.0900103. [DOI] [PubMed] [Google Scholar]
  3. Caro J. F., Amatruda J. M. Insulin receptors in hepatocytes: postreceptor events mediate down regulation. Science. 1980 Nov 28;210(4473):1029–1031. doi: 10.1126/science.7001632. [DOI] [PubMed] [Google Scholar]
  4. Conney A. H. Pharmacological implications of microsomal enzyme induction. Pharmacol Rev. 1967 Sep;19(3):317–366. [PubMed] [Google Scholar]
  5. Czech M. P. Insulin action. Am J Med. 1981 Jan;70(1):142–150. doi: 10.1016/0002-9343(81)90421-6. [DOI] [PubMed] [Google Scholar]
  6. DeFronzo R. A., Ferrannini E. The pathogenesis of non-insulin-dependent diabetes: an update. Medicine (Baltimore) 1982 May;61(3):125–140. doi: 10.1097/00005792-198205000-00001. [DOI] [PubMed] [Google Scholar]
  7. DeFronzo R. A., Tobin J. D., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979 Sep;237(3):E214–E223. doi: 10.1152/ajpendo.1979.237.3.E214. [DOI] [PubMed] [Google Scholar]
  8. Feely J., Wilkinson G. R., Wood A. J. Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med. 1981 Mar 19;304(12):692–695. doi: 10.1056/NEJM198103193041202. [DOI] [PubMed] [Google Scholar]
  9. Fink R. I., Kolterman O. G., Griffin J., Olefsky J. M. Mechanisms of insulin resistance in aging. J Clin Invest. 1983 Jun;71(6):1523–1535. doi: 10.1172/JCI110908. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gachályi B., Káldor A., Szeberényi S. m-Trifluoromethyl-alpha-ethylbenzhydrol: a new enzyme inducer. Eur J Clin Pharmacol. 1978 Jun 19;13(4):299–302. doi: 10.1007/BF00716366. [DOI] [PubMed] [Google Scholar]
  11. Kolterman O. G., Gray R. S., Shapiro G., Scarlett J. A., Griffin J., Olefsky J. M. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Diabetes. 1984 Apr;33(4):346–354. doi: 10.2337/diab.33.4.346. [DOI] [PubMed] [Google Scholar]
  12. Kolterman O. G., Insel J., Saekow M., Olefsky J. M. Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects. J Clin Invest. 1980 Jun;65(6):1272–1284. doi: 10.1172/JCI109790. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lahtela J. T., Arranto A. J., Sotaniemi E. A. Enzyme inducers improve insulin sensitivity in non-insulin-dependent diabetic subjects. Diabetes. 1985 Sep;34(9):911–916. doi: 10.2337/diab.34.9.911. [DOI] [PubMed] [Google Scholar]
  14. Lahtela J. T., Särkkä P., Sotaniemi E. A. Phenobarbital treatment enhances insulin mediated glucose metabolism in man. Res Commun Chem Pathol Pharmacol. 1984 May;44(2):215–226. [PubMed] [Google Scholar]
  15. Nordlie R. C. Multifunctional glucose-6-phosphatase: cellular biology. Life Sci. 1979 Jun 25;24(26):2397–2404. doi: 10.1016/0024-3205(79)90447-8. [DOI] [PubMed] [Google Scholar]
  16. Olefsky J. M., Kolterman O. G. Mechanisms of insulin resistance in obesity and noninsulin-dependent (type II) diabetes. Am J Med. 1981 Jan;70(1):151–168. doi: 10.1016/0002-9343(81)90422-8. [DOI] [PubMed] [Google Scholar]
  17. Olefsky J. M. LIlly lecture 1980. Insulin resistance and insulin action. An in vitro and in vivo perspective. Diabetes. 1981 Feb;30(2):148–162. doi: 10.2337/diab.30.2.148. [DOI] [PubMed] [Google Scholar]
  18. Pirttiaho H. I., Sotaniemi E. A., Pelkonen R. O., Pitkänen U. Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants. Eur J Clin Pharmacol. 1982;22(5):441–445. doi: 10.1007/BF00542550. [DOI] [PubMed] [Google Scholar]
  19. Prescott L. F., Adjepon-Yamoah K. K., Roberts E. Rapid gas-liquid chromatographic estimation of antipyrine in plasma. J Pharm Pharmacol. 1973 Mar;25(3):205–207. doi: 10.1111/j.2042-7158.1973.tb10625.x. [DOI] [PubMed] [Google Scholar]
  20. Proietto J., Alford F. P., Dudley F. J. The mechanism of the carbohydrate intolerance of cirrhosis. J Clin Endocrinol Metab. 1980 Nov;51(5):1030–1036. doi: 10.1210/jcem-51-5-1030. [DOI] [PubMed] [Google Scholar]
  21. Puurunen J., Pelkonen O. Cimetidine inhibits microsomal drug metabolism in the rat. Eur J Pharmacol. 1979 May 1;55(3):335–336. doi: 10.1016/0014-2999(79)90205-x. [DOI] [PubMed] [Google Scholar]
  22. Puurunen J., Sotaniemi E., Pelkonen O. Effect of cimetidine on microsomal drug metabolism in man. Eur J Clin Pharmacol. 1980 Aug;18(2):185–187. doi: 10.1007/BF00561588. [DOI] [PubMed] [Google Scholar]
  23. REMMER H., MERKER H. J. [Enzyme induction and increase of endoplasmic reticulum in liver cells during phenobarbital (Luminal) therapy]. Klin Wochenschr. 1963 Mar 15;41:276–282. doi: 10.1007/BF01483392. [DOI] [PubMed] [Google Scholar]
  24. Reaven G. M. Insulin resistance in noninsulin-dependent diabetes mellitus. Does it exist and can it be measured? Am J Med. 1983 Jan 17;74(1A):3–17. doi: 10.1016/0002-9343(83)90650-2. [DOI] [PubMed] [Google Scholar]
  25. Savolainen M. J., Arranto A. J., Hassinen I. E., Luoma P. V., Pelkonen R. O., Sotaniemi E. A. Relationship between lipid composition and drug metabolizing capacity of human liver. Eur J Clin Pharmacol. 1985;27(6):727–732. doi: 10.1007/BF00547057. [DOI] [PubMed] [Google Scholar]
  26. Scholz R., Hansen W., Thurman R. G. Interaction of mixed-function oxidation with biosynthetic processes. 1. Inhibition of gluconeogenesis by aminopyrine in perfused rat liver. Eur J Biochem. 1973 Sep 21;38(1):64–72. doi: 10.1111/j.1432-1033.1973.tb03034.x. [DOI] [PubMed] [Google Scholar]
  27. Serlin M. J., Sibeon R. G., Mossman S., Breckenridge A. M., Williams J. R., Atwood J. L., Willoughby J. M. Cimetidine: interaction with oral anticoagulants in man. Lancet. 1979 Aug 18;2(8138):317–319. doi: 10.1016/s0140-6736(79)90340-4. [DOI] [PubMed] [Google Scholar]
  28. Sherwin R. S., Kramer K. J., Tobin J. D., Insel P. A., Liljenquist J. E., Berman M., Andres R. A model of the kinetics of insulin in man. J Clin Invest. 1974 May;53(5):1481–1492. doi: 10.1172/JCI107697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Sotaniemi E. A., Ahlqvist J., Pelkonen R. O., Pirttiaho H., Luoma P. V. Histological changes in the liver and indices of drug metabolism in alcoholics. Eur J Clin Pharmacol. 1977 Apr 20;11(4):295–303. doi: 10.1007/BF00607680. [DOI] [PubMed] [Google Scholar]
  30. Sotaniemi E. A., Arranto A. J., Sutinen S., Stengård J. H., Sutinen S. Treatment of noninsulin-dependent diabetes mellitus with enzyme inducers. Clin Pharmacol Ther. 1983 Jun;33(6):826–835. doi: 10.1038/clpt.1983.113. [DOI] [PubMed] [Google Scholar]
  31. Sotaniemi E. A., Stengård J. H., Saarni H. U., Arranto A. J., Keinänen K., Kerola T., Sutinen S. Hepatic glucose-6-phosphatase activity in non-insulin dependent diabetics. Effect of enzyme-inducing drugs. Acta Med Scand. 1984;215(4):323–331. doi: 10.1111/j.0954-6820.1984.tb05014.x. [DOI] [PubMed] [Google Scholar]
  32. Stengård J. H., Saarni H. U., Sotaniemi E. A. Effects of medroxyprogesterone acetate on hepatic glucose metabolism and microsomal enzyme activity in rats with normal and altered liver. Pharmacology. 1984;28(1):34–41. doi: 10.1159/000137940. [DOI] [PubMed] [Google Scholar]
  33. Thurman R. G., Reinke L. A., Belinsky S., Evans R. K., Kauffman F. C. Co-regulation of the mixed-function oxidation of p-nitroanisole and glucuronidation of p-nitrophenol in the perfused rat liver by carbohydrate reserves. Arch Biochem Biophys. 1981 Jun;209(1):137–142. doi: 10.1016/0003-9861(81)90265-4. [DOI] [PubMed] [Google Scholar]
  34. Thurman R. G., Scholz R. Mixed function oxidation in perfused rat liver. The effect of aminopyrine on oxygen uptake. Eur J Biochem. 1969 Oct;10(3):459–467. doi: 10.1111/j.1432-1033.1969.tb00711.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES